|
|
Article: Altus Pharmaceuticals Realigns Product Development Priorities and Focuses on Long-Acting Growth Hormone Candidate ALTU-238.
- Article from:
- Business Wire
- Article date:
- January 26, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WALTHAM, Mass. -- Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced a strategic realignment of product development priorities to focus on the advancement of the Company's breakthrough, long-acting, recombinant human growth hormone candidate, ALTU-238, as a once-per-week treatment for adult and pediatric patients with growth hormone deficiency. To conserve capital resources, Altus will discontinue its Trizytek program activities. This discontinuation will result in the transfer of certain Trizytek intellectual property rights and regulatory filings to Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, in ...
Related newspaper, magazine, and journal articles:
|
|
Article: Altus Pharmaceuticals Appoints Lauren Sabella Vice ...
Business Wire;
May 1, 2006 ;
663 words
... ... CAMBRIDGE, Mass. -- Altus Pharmaceuticals Inc ... Sabella has been appointed Vice President, Commercial Development ... Sabella will lead Altus' commercialization ... Prior to joining Altus, Ms. Sabella was employed ... Sabella served as Vice President Sales, Eastern Zone ...
|
|